Reported results
- Total revenue was $5,139,298 thousand for the third quarter of 2026 compared to $2,985,984 thousand for the third quarter of 2025.
- Medical loss ratio (“MLR”) was 84.0% for the third quarter of 2026 compared to 88.5% for the third quarter of 2025.
- Selling, general, and administrative (“SG&A”) expense ratio was 14.0% for the third quarter of 2026 compared to 17.5% for the third quarter of 2025.
- Earnings from operations were $178,018 thousand for the third quarter of 2026 compared to a loss from operations of $(129,250) thousand for the third quarter of 2025.
- Net income attributable to Oscar Health, Inc. was $167,281 thousand for the third quarter of 2026 compared to a net loss of $(137,450) thousand for the third quarter of 2025.
- Adjusted EBITDA was $206,852 thousand for the third quarter of 2026 compared to an adjusted EBITDA loss of $(101,453) thousand for the third quarter of 2025.
Guidance
- Total revenue: $19.0 billion to $19.3 billion
- Medical loss ratio: 80.5% to 81.5%
- SG&A expense ratio: 15.1% to 15.6%
- Earnings from operations: $850 million to $950 million
Price and volatility reaction
The stock moved -5.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -11.8 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 35.19 | 2026-11-04 |
| Close after release | 33.18 | 2026-11-05 |
| Realised move | -5.7% | close to close |
| 30d ATM IV change | -11.8 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
